Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 6/20 | 0.41 |
| ▸ | ACVRL1 | P37023 | 5/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 5/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.36 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.36 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.36 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22132915 | 0.75 | ACVRL1 (0.58) | PIK3CDACVRL1MTORRICTORRPTOR | |
| SCHEMBL16655489 | 0.75 | MAP4K4 (0.41) | PIK3CDACVRL1TNK2PIK3CAPIK3CB | |
| SCHEMBL16655468 | 0.73 | ACVRL1 (0.53) | PIK3CDACVRL1 | |
| SCHEMBL29388440 | 0.71 | ACVRL1 (0.39) | PIK3CDACVRL1AXLMERTK | |
| SCHEMBL22695926 | 0.69 | ACVRL1 (0.37) | PIK3CDACVRL1MTORRICTORRPTOR | |
| SCHEMBL22132863 | 0.68 | RIPK1 (0.48) | PIK3CDTNK2AXLMERTK | |
| SCHEMBL22132905 | 0.68 | RIPK1 (0.48) | PIK3CDTNK2AXLMERTK | |
| SCHEMBL22132930 | 0.68 | RIPK1 (0.48) | PIK3CDTNK2AXLMERTK | |
| SCHEMBL22132768 | 0.68 | EGFR (0.45) | PIK3CDACVRL1 | |
| SCHEMBL22132857 | 0.68 | RIPK1 (0.46) | TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| EP-3057970-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | PIK3CD 2/4885ACVRL1 4469/4885TNK2 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.